ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 303,28
0,66%
Dow Jones
45 014,04
0,69%
DAX
20 232,14
0,98%
Brent Oil
72,355
-1,70%
Bitcoin
98 934,14
3,09%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. IO Biotech Inc (IOBT)

  7. IO Biotech Inc (IOBT) Actualités

IOBT

IO Biotech (IOBT)

IO Biotech Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:IOBT
DateHeureSourceTitreSymboleSociété
12/11/202422h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IOBTIO Biotech Inc
12/11/202413h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
12/11/202413h05GlobeNewswire Inc.IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:IOBTIO Biotech Inc
11/11/202422h05GlobeNewswire Inc.IO Biotech Announces Participation in Upcoming Investor ConferencesNASDAQ:IOBTIO Biotech Inc
07/11/202416h00GlobeNewswire Inc.IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 StudyNASDAQ:IOBTIO Biotech Inc
04/10/202415h00GlobeNewswire Inc.IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingNASDAQ:IOBTIO Biotech Inc
14/09/202408h30GlobeNewswire Inc.IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck CancerNASDAQ:IOBTIO Biotech Inc
30/08/202422h05GlobeNewswire Inc.IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced MelanomaNASDAQ:IOBTIO Biotech Inc
13/08/202413h05GlobeNewswire Inc.IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:IOBTIO Biotech Inc
25/07/202422h05GlobeNewswire Inc.IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024NASDAQ:IOBTIO Biotech Inc
07/06/202422h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IOBTIO Biotech Inc
23/05/202414h30GlobeNewswire Inc.IO Biotech to Present at Jefferies Global Healthcare ConferenceNASDAQ:IOBTIO Biotech Inc
14/05/202413h55GlobeNewswire Inc.IO Biotech Reports First Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:IOBTIO Biotech Inc
24/04/202422h30GlobeNewswire Inc.IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:IOBTIO Biotech Inc
15/04/202414h30GlobeNewswire Inc.IO Biotech Expands Senior Leadership Team to Progress Commercialization ReadinessNASDAQ:IOBTIO Biotech Inc
09/04/202418h00GlobeNewswire Inc.IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103NASDAQ:IOBTIO Biotech Inc
05/04/202414h30GlobeNewswire Inc.IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business OfficerNASDAQ:IOBTIO Biotech Inc
11/03/202421h56Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IOBTIO Biotech Inc
06/03/202422h11GlobeNewswire Inc.IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:IOBTIO Biotech Inc
05/03/202423h17Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IOBTIO Biotech Inc
05/03/202422h40GlobeNewswire Inc.IO Biotech Announces 2023 Fourth-Quarter and Year-End ResultsNASDAQ:IOBTIO Biotech Inc
26/02/202422h05GlobeNewswire Inc.IO Biotech to Present at 44th Annual Cowen Health Care ConferenceNASDAQ:IOBTIO Biotech Inc
21/12/202314h30GlobeNewswire Inc.IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket TrialNASDAQ:IOBTIO Biotech Inc
13/11/202314h12GlobeNewswire Inc.IO Biotech Announces 2023 Third Quarter ResultsNASDAQ:IOBTIO Biotech Inc
13/11/202314h00GlobeNewswire Inc.IO Biotech Appoints Helen Collins, MD, to its Board of DirectorsNASDAQ:IOBTIO Biotech Inc
10/11/202314h00GlobeNewswire Inc.IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced MelanomaNASDAQ:IOBTIO Biotech Inc
01/11/202313h30GlobeNewswire Inc.IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:IOBTIO Biotech Inc
23/10/202307h00GlobeNewswire Inc.Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European SocieNASDAQ:IOBTIO Biotech Inc
03/10/202322h30GlobeNewswire Inc.IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:IOBTIO Biotech Inc
12/09/202322h06Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NASDAQ:IOBTIO Biotech Inc
 Showing the most relevant articles for your search:NASDAQ:IOBT

Dernières Valeurs Consultées

EU
RI
Pernod Ricard
NYSE
MRK
Merck
FTSE
UKX
FTSE 100
EU
VK
Vallourec
NYSE
DIS
Walt Disney
EU
BNP
BNP Paribas
EU
BEL20
Bel 20
NASDAQ
AAPL
Apple
EU
DG
Vinci
COIN
SOLUSD
Solana
EU
LR
Legrand
EU
HO
Thales
EU
ORA
Orange
NASDAQ
NVDA
NVIDIA
EU
ML
Michelin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés